WAM
RNAZ icon

Warberg Asset Management’s TransCode Therapeutics RNAZ Stock Holding History

Warberg Asset Management’s Portfolio RNAZ Stock Details RNAZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,786
Closed -$24.8K – 213
2025
Q1 		$24.8K Buy
+1,786
New +$229K ﹤0.01% 140
2023
Q4 		– Hold
0
– -$5.03K – 259
2023
Q3 		– Hold
0
– – – 199
2023
Q2 		– Hold
0
– -$6.77K – 261
2023
Q1 		– Hold
0
– – – 209

Other funds holding RNAZ

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SC
SouthState Corp Winter Haven, Florida $2.14B AUM 18.39% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Warberg Asset Management's RNAZ Position: Q2 2025 in Review

Warberg Asset Management sold out of TransCode Therapeutics (RNAZ) in Q2 2025, closing a stake of 1,786 shares — an estimated $24.8K sold.

Warberg Asset Management first reported a position in RNAZ in Q1 2025 and held it in 1 quarter. The position peaked at $24.8K in Q1 2025. 9 funds tracked by Wall St. Rank hold RNAZ as of Q2 2025.

  • Warberg Asset Management reported no remaining TransCode Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Warberg Asset Management sold 1,786 TransCode Therapeutics shares in Q2 2025, an estimated $24.8K.
  • Warberg Asset Management first reported a position in TransCode Therapeutics in Q1 2025 and held it in 1 quarter.
  • Warberg Asset Management's TransCode Therapeutics position peaked at $24.8K in Q1 2025.
  • 9 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q2 2025.

Based on Warberg Asset Management's 13F filing for Q2 2025, filed 12 Aug 2025.